EyePoint Pharmaceuticals US, Inc.
$9.7M 748 recipients
Compare payment profiles
CMS Open Payments · Program Year 2024
Route 92 Medical, Inc.
Route 92 Medical, Inc. reported $9,674,355.13 across General Payments, Research, and Ownership to 774 physicians and teaching hospitals across 812 transactions.
- $9.7M
- All-tracks total
- 812
- Transactions
- 774
- Recipients
- +$328.3K
- General Payments vs PY2023
Route 92 Medical, Inc. reported $9,674,355.13 across all CMS Open Payments tracks (General + Research + Ownership) to 774 physicians and teaching hospitals in Program Year 2024 - ranking #180 of 1,925 reporting manufacturers (0.1% of the all-tracks industry total); General Payments alone were $704,691.25, averaging $12.5K per recipient.
Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.
CMS Sunshine Act warrant
Manufacturer route-92-medical-inc Route 92 Medical, Inc.
$9.7M · #180/1,925 · 0.1% industry · PY2024
- TOT $9.7M
- RANK #180
- SHARE 0.1%
- TXN 812
- RCP 774
- CAT 4
- GEN $704.7K
- ΔGEN +$328.3K
- TOP1 37.6%
- PY 2024
Volume peers
Nearest volume peer: EyePoint Pharmaceuticals US, Inc. ($9.7M)
Route 92 Medical, Inc. sits among 1,925 manufacturers disclosing under the Physician Payments Sunshine Act. Volume peers below are nearest by all-tracks total, not corporate affiliates. Open the company rankings →
Release-over-release change
General Payments changed from PY2023 to PY2024
Route 92 Medical, Inc.'s CMS-reported General Payments increased by $328.3K (+87.2%) from PY2023 to PY2024.
How this year-over-year comparison is scoped
The comparison uses consecutive CMS program years only (current = prior + 1) from the manufacturer General Payments summary and excludes research and ownership or investment records. Non-consecutive year pairs are not shown as year-over-year change. This General Payments figure is not the all-tracks company total in the hero.
CMS source labels for this exact identifier: PY2022: ROUTE 92 MEDICAL, INC.PY2023: ROUTE 92 MEDICAL, INC.PY2024: Route 92 Medical, Inc.. Matching identifiers support a bounded record comparison; a label difference would be reported as unresolved rather than treated as a corporate event.
Subscribe to this company's source-bounded update feed It publishes only identifier-matched CMS release comparisons, never inferred company events.
General Payments: PY2023 vs PY2024
Annual CMS-reported totals for this company, not an all-category Open Payments total
- PY2023
- $376,394.51
- PY2024
- $704,691.25
What the Data Shows for Route 92 Medical, Inc.
$9,674,355.13: that is what Route 92 Medical, Inc. reported in payments to 774 physicians and teaching hospitals during Program Year 2024, spread across 812 transactions ($11.9K per transaction, $12.5K per recipient). The company sits at rank #180 of 1,925, a comparatively small 0.1% slice of all industry payments reported nationwide for the year.
60 transactions worth $644.6K make "Consulting Fee" the top general-payment category in the 4-category breakdown below, 91.5% of General Payments (see our methodology for how research and ownership payments are reported separately).
General Payment Breakdown by Type
Across 4 types of general payments, Route 92 Medical, Inc.'s largest category was "Consulting Fee" at $644.6K - 91.5% of General Payments.
Route 92 Medical, Inc. reports 4 general-payment categories - the top three are Consulting Fee (91.5%), Food and Beverage (5.5%), and Travel and Lodging (3.0%). The remaining 1 category make up 0.0% of this company's reported general-payment total. That multi-category mix is the kind of profile single-category reporters cannot show.
How Route 92 Medical, Inc. divides its payments
How the reported total splits across payment categories
| Payment Type | Amount | Transactions | % of Total |
|---|---|---|---|
| Consulting Fee | $644.6K | 60 | 91.5% |
| Food and Beverage | $38.9K | 672 | 5.5% |
| Travel and Lodging | $21.0K | 40 | 3.0% |
| Entertainment | $245.02 | 2 | 0.0% |
Recipient Concentration in General Payments
The five largest recipient relationships account for $604,639.11 (85.8%) of $704,691.25 in this company's General Payments records across 290 recipients.
General Payments scope note
Program Year 2024 General Payments view only: excludes research and ownership/investment records, so it is not the all-category company total above.
Largest General-Payment relationships for Route 92 Medical, Inc.
The five named recipients with the highest reported General Payments from this company
- 1
Fabio Settecase
$264,725.47 across 14 reported transactions
- 2
Warren Kim
$116,252.40 across 27 reported transactions
- 3
Matthew Alexander
$110,061.51 across 15 reported transactions
- 4
Joey English
$98,269.62 across 40 reported transactions
- 5
Ajit Puri
$15,330.11 across 9 reported transactions
Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.
Similarly Concentrated Companies
Companies whose General Payments are spread across recipients about as (un)evenly as Route 92 Medical, Inc.'s, measured by the same HHI concentration index above, not by payment size.
What HHI 2,500 means here
2,500 is the DOJ/FTC merger-guidelines threshold for "highly concentrated" markets; used here only as a familiar concentration reference, not a legal finding about Route 92 Medical, Inc..
Companies with Similar Payment Volumes
Open a profile or compare a similar company's CMS-reported payment pattern with Route 92 Medical, Inc..
Showing 6 of 1,924 companies with CMS-reported payment data.
Dermavant Sciences, Inc.
$9.7M 73,486 recipients
Compare payment profiles
Supernus Pharmaceuticals, Inc.
$9.7M 61,253 recipients
Compare payment profiles
H. Lundbeck A S
$9.8M 303 recipients
Compare payment profiles
W. L. Gore & Associates, Inc.
$9.5M 25,860 recipients
Compare payment profiles
Applied Medical Research, Inc
$10.0M 0 recipients
Compare payment profiles
Data sourced from CMS Open Payments (Physician Payments Sunshine Act). See our methodology for details. Retrieved and formatted by PlainPharmaWatch
Disclaimer
This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.
Read our methodology - how this data is sourced, computed, and verified.
Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-26.